# Chapter-17

# Chemotherapy of Malignancy-II

**Mrs. Durgesh Kumari Gupta**
Assistant Professor
Rajiv Gandhi Institute of Pharmacy
Faculty of Pharmaceutical Science & Technology
AKS University Satna, MP-India

**ABSTRACT**

Chemotherapy is a pivotal treatment modality in the fight against malignancies, leveraging potent drugs to target and eradicate cancer cells. It operates by disrupting the cellular mechanisms essential for cancer cell proliferation and survival, thereby inhibiting tumor growth. These drugs can be administered orally, intravenously, or through other routes, allowing for flexibility in treatment plans. Chemotherapy regimens are often tailored to the specific type and stage of cancer, with protocols designed to maximize efficacy while minimizing adverse effects. Despite its benefits, chemotherapy is accompanied by a range of side effects due to its impact on rapidly dividing healthy cells, such as those in the bone marrow, gastrointestinal tract, and hair follicles. The choice of chemotherapy agents and their combinations is guided by the cancer's histological characteristics, genetic markers, and the patient's overall health. Advances in pharmacogenomics have enabled more personalized chemotherapy approaches, improving outcomes and reducing toxicity. Chemotherapy can be used as a primary treatment or in conjunction with surgery and radiation therapy, enhancing the overall efficacy of cancer management. Neoadjuvant chemotherapy aims to shrink tumors before surgical intervention, while adjuvant chemotherapy targets residual cancer cells post-surgery. Supportive care measures, such as antiemetics, growth factors, and hydration therapy, are critical in managing the side effects and maintaining the patient's quality of life during treatment. Regular monitoring and adjustments to the chemotherapy regimen help mitigate adverse reactions and ensure optimal therapeutic responses. Research continues to evolve, with new chemotherapy agents and combination therapies being developed to overcome resistance and improve survival rates. As a cornerstone of oncology, chemotherapy remains a dynamic and essential component in the comprehensive treatment of malignancies, offering hope and extending lives for many cancer patients.

## Introduction to Chemotherapy of Malignancy

Chemotherapy is a cornerstone in the treatment of malignancies, utilizing powerful drugs to target and destroy cancer cells. Unlike localized treatments such as surgery and radiation therapy, chemotherapy works systemically, making it effective against cancer cells that have spread throughout the body. The primary objective of chemotherapy is to eradicate cancer cells, reduce tumor size, prevent metastasis, and alleviate symptoms. Chemotherapy can be used alone or in combination with other treatments to enhance overall efficacy. Despite its therapeutic benefits, chemotherapy can affect healthy cells, leading to side effects that require careful management. Advances in chemotherapy drugs and personalized medicine continue to improve the precision and effectiveness of cancer treatment.

Chemotherapy of malignancy, often referred to simply as chemotherapy, is a medical treatment approach aimed at using drugs to destroy or inhibit the growth of cancer cells. Malignancy refers to the property of being cancerous or having the potential to invade and spread to other tissues in an uncontrolled manner. Chemotherapy is a systemic treatment, meaning it affects the entire body, and it is commonly used to treat various types of cancers.

**Classification of Chemotherapy Drugs**

Chemotherapy drugs can be classified based on their chemical structure, mechanism of action, and cell cycle specificity. Here are some of the main categories:

1. **Alkylating Agents**
    - **Examples:** Cyclophosphamide, Ifosfamide, Melphalan
    - **Mechanism:** These drugs work by adding alkyl groups to DNA, leading to DNA cross-linking and strand breaks, which ultimately inhibit DNA replication and transcription, causing cell death. They are effective throughout the cell cycle but are particularly potent during the DNA synthesis phase (S-phase).
2. **Antimetabolites**
    - **Examples:** Methotrexate, 5-Fluorouracil (5-FU), Cytarabine
    - **Mechanism:** Antimetabolites resemble natural substances within the cell, interfering with DNA and RNA synthesis by substituting for normal building blocks of RNA and DNA. This results in faulty DNA synthesis and cell death, particularly affecting rapidly dividing cells in the S-phase of the cell cycle.
3. **Mitotic Inhibitors**
    - **Examples:** Paclitaxel, Docetaxel, Vincristine, Vinblastine
    - **Mechanism:** These drugs inhibit cell division by disrupting the microtubule structures that are necessary for mitosis (M-phase). They prevent cells from successfully completing mitosis, leading to cell death.
4. **Topoisomerase Inhibitors**
    - **Examples:** Doxorubicin, Etoposide, Irinotecan
    - **Mechanism:** These drugs interfere with the enzymes topoisomerase I and II, which are essential for DNA replication and repair. Inhibition of these enzymes results in DNA strand breaks and cell death.
5. **Antitumor Antibiotics**
    - **Examples:** Doxorubicin, Bleomycin, Mitomycin C
    - **Mechanism:** Derived from natural products, these drugs intercalate into DNA strands, inhibiting RNA synthesis and causing breaks in DNA. They are effective in various phases of the cell cycle.
6. **Hormonal Agents**
    - **Examples:** Tamoxifen, Letrozole, Leuprolide

- **Mechanism:** These drugs are used in cancers that are hormone-dependent, such as breast and prostate cancers. They work by blocking hormone receptors or decreasing hormone production, thereby inhibiting cancer cell growth.

7. **Targeted Therapy**
    - **Examples:** Imatinib, Trastuzumab, Erlotinib
    - **Mechanism:** These drugs target specific molecules involved in cancer cell growth and survival, such as tyrosine kinases or HER2 receptors. They offer a more precise approach to cancer treatment with potentially fewer side effects compared to traditional chemotherapy.

8. **Immunotherapy**
    - **Examples:** Pembrolizumab, Nivolumab, Ipilimumab
    - **Mechanism:** Immunotherapy drugs enhance the body's immune response against cancer cells. They work by targeting immune checkpoints, modulating immune cell activity, or using engineered immune cells to attack cancer.

**Introduction to Chemotherapy of Malignancy**

Chemotherapy is a cornerstone in the treatment of malignancies, utilizing powerful drugs to target and destroy cancer cells. Unlike localized treatments such as surgery and radiation therapy, chemotherapy works systemically, making it effective against cancer cells that have spread throughout the body. The primary objective of chemotherapy is to eradicate cancer cells, reduce tumor size, prevent metastasis, and alleviate symptoms. Chemotherapy can be used alone or in combination with other treatments to enhance overall efficacy. Despite its therapeutic benefits, chemotherapy can affect healthy cells, leading to side effects that require careful management. Advances in chemotherapy drugs and personalized medicine continue to improve the precision and effectiveness of cancer treatment.

**Classification of Chemotherapy Drugs**

Chemotherapy drugs can be classified based on their chemical structure, mechanism of action, and cell cycle specificity. Here are some of the main categories:

1. **Alkylating Agents**
    - **Examples:** Cyclophosphamide, Ifosfamide, Melphalan
    - **Mechanism:** These drugs work by adding alkyl groups to DNA, leading to DNA cross-linking and strand breaks, which ultimately inhibit DNA replication and transcription, causing cell death. They are effective throughout the cell cycle but are particularly potent during the DNA synthesis phase (S-phase).

2. **Antimetabolites**
    - **Examples:** Methotrexate, 5-Fluorouracil (5-FU), Cytarabine
    - **Mechanism:** Antimetabolites resemble natural substances within the cell, interfering with DNA and RNA synthesis by substituting for normal building blocks of RNA and

DNA. This results in faulty DNA synthesis and cell death, particularly affecting rapidly dividing cells in the S-phase of the cell cycle.

3. **Mitotic Inhibitors**
    - **Examples:** Paclitaxel, Docetaxel, Vincristine, Vinblastine
    - **Mechanism:** These drugs inhibit cell division by disrupting the microtubule structures that are necessary for mitosis (M-phase). They prevent cells from successfully completing mitosis, leading to cell death.

4. **Topoisomerase Inhibitors**
    - **Examples:** Doxorubicin, Etoposide, Irinotecan
    - **Mechanism:** These drugs interfere with the enzymes topoisomerase I and II, which are essential for DNA replication and repair. Inhibition of these enzymes results in DNA strand breaks and cell death.

5. **Antitumor Antibiotics**
    - **Examples:** Doxorubicin, Bleomycin, Mitomycin C
    - **Mechanism:** Derived from natural products, these drugs intercalate into DNA strands, inhibiting RNA synthesis and causing breaks in DNA. They are effective in various phases of the cell cycle.

6. **Hormonal Agents**
    - **Examples:** Tamoxifen, Letrozole, Leuprolide
    - **Mechanism:** These drugs are used in cancers that are hormone-dependent, such as breast and prostate cancers. They work by blocking hormone receptors or decreasing hormone production, thereby inhibiting cancer cell growth.

7. **Targeted Therapy**
    - **Examples:** Imatinib, Trastuzumab, Erlotinib
    - **Mechanism:** These drugs target specific molecules involved in cancer cell growth and survival, such as tyrosine kinases or HER2 receptors. They offer a more precise approach to cancer treatment with potentially fewer side effects compared to traditional chemotherapy.

8. **Immunotherapy**
    - **Examples:** Pembrolizumab, Nivolumab, Ipilimumab
    - **Mechanism:** Immunotherapy drugs enhance the body's immune response against cancer cells. They work by targeting immune checkpoints, modulating immune cell activity, or using engineered immune cells to attack cancer.

**Pharmacology of Chemotherapy Drugs**

Chemotherapy drugs are used to treat various malignancies, and understanding their pharmacology is essential for optimizing their therapeutic effects while minimizing adverse

reactions. Here's a detailed look at their mechanisms of action, pharmacokinetics, adverse effects, and uses:

## 1. Alkylating Agents

**Examples:** Cyclophosphamide, Ifosfamide, Melphalan

### Mechanism of Action

Alkylating agents add alkyl groups to DNA bases, causing DNA cross-linking and strand breaks. This interferes with DNA replication and transcription, leading to cell cycle arrest and apoptosis.

### Pharmacokinetics

- **Absorption:** Often administered intravenously or orally.
- **Distribution:** Widely distributed in the body, including the central nervous system for some agents.
- **Metabolism:** Metabolized primarily in the liver.
- **Excretion:** Excreted mainly via urine.

### Adverse Effects

- Myelosuppression (bone marrow suppression)
- Nausea and vomiting
- Alopecia (hair loss)
- Hemorrhagic cystitis (especially with cyclophosphamide and ifosfamide)

### Uses

- Hodgkin's and non-Hodgkin's lymphomas
- Breast cancer
- Ovarian cancer
- Multiple myeloma

## 2. Antimetabolites

**Examples:** Methotrexate, 5-Fluorouracil (5-FU), Cytarabine

### Mechanism of Action

Antimetabolites mimic natural substrates and interfere with DNA and RNA synthesis. For example, methotrexate inhibits dihydrofolate reductase, reducing the synthesis of thymidylate and purines necessary for DNA synthesis.

### Pharmacokinetics

- **Absorption:** Oral and intravenous administration.
- **Distribution:** Methotrexate can cross the blood-brain barrier.
- **Metabolism:** Hepatic metabolism; some drugs are activated intracellularly.
- **Excretion:** Renal excretion is significant.

**Adverse Effects**

- Myelosuppression
- Mucositis (inflammation of the mucous membranes)
- Hepatotoxicity
- Renal toxicity (particularly with methotrexate)

**Uses**

- Leukemias
- Breast cancer
- Gastrointestinal cancers
- Osteosarcoma

**3. Mitotic Inhibitors**

**Examples:** Paclitaxel, Docetaxel, Vincristine, Vinblastine

**Mechanism of Action**

Mitotic inhibitors disrupt microtubule dynamics, preventing mitosis. Taxanes (paclitaxel, docetaxel) stabilize microtubules, while vinca alkaloids (vincristine, vinblastine) inhibit microtubule formation.

**Pharmacokinetics**

- **Absorption:** Administered intravenously.
- **Distribution:** Widely distributed; high affinity for tubulin.
- **Metabolism:** Hepatic metabolism (cytochrome P450 enzymes).
- **Excretion:** Primarily biliary excretion.

**Adverse Effects**

- Myelosuppression
- Peripheral neuropathy
- Alopecia
- Hypersensitivity reactions (particularly with paclitaxel)

**Uses**

- Breast cancer
- Ovarian cancer
- Lung cancer
- Hodgkin's lymphoma

**4. Topoisomerase Inhibitors**

**Examples:** Doxorubicin, Etoposide, Irinotecan

**Mechanism of Action**

Topoisomerase inhibitors interfere with DNA replication by stabilizing the transient breaks made by topoisomerase enzymes, leading to DNA damage and apoptosis.

**Pharmacokinetics**

- **Absorption:** Intravenous administration.
- **Distribution:** Widely distributed; doxorubicin has high tissue binding.
- **Metabolism:** Hepatic metabolism; irinotecan is a prodrug converted to active SN-38.
- **Excretion:** Primarily biliary and renal excretion.

**Adverse Effects**

- Myelosuppression
- Cardiotoxicity (especially doxorubicin)
- Gastrointestinal toxicity (diarrhea with irinotecan)
- Secondary malignancies

**Uses**

- Breast cancer
- Lung cancer
- Ovarian cancer
- Leukemias

**5. Antitumor Antibiotics**

**Examples:** Doxorubicin, Bleomycin, Mitomycin C

**Mechanism of Action**

These drugs intercalate into DNA, inhibiting RNA synthesis and causing DNA strand breaks. They generate free radicals that damage cellular components.

**Pharmacokinetics**

- **Absorption:** Administered intravenously.
- **Distribution:** Extensive tissue binding; doxorubicin accumulates in the heart.
- **Metabolism:** Primarily hepatic.
- **Excretion:** Biliary and renal excretion.

**Adverse Effects**

- Myelosuppression
- Cardiotoxicity (doxorubicin)
- Pulmonary toxicity (bleomycin)
- Mucositis

**Uses**

- Breast cancer

- Lung cancer
- Lymphomas
- Sarcomas

**6. Hormonal Agents**

**Examples:** Tamoxifen, Letrozole, Leuprolide

**Mechanism of Action:**

Hormonal agents block hormone receptors or decrease hormone production. Tamoxifen is an estrogen receptor antagonist, while letrozole is an aromatase inhibitor, and leuprolide is a GnRH agonist that suppresses gonadotropin release.

**Pharmacokinetics**

- **Absorption:** Oral administration.
- **Distribution:** High protein binding.
- **Metabolism:** Hepatic metabolism.
- **Excretion:** Renal and biliary excretion.

**Adverse Effects**

- Hot flashes
- Bone loss (aromatase inhibitors)
- Cardiovascular risk (tamoxifen)
- Tumor flare (leuprolide)

**Uses**

- Breast cancer
- Prostate cancer

**7. Targeted Therapy**

**Examples:** Imatinib, Trastuzumab, Erlotinib

**Mechanism of Action**

Targeted therapies specifically inhibit molecules involved in cancer cell signaling and growth. Imatinib inhibits BCR-ABL tyrosine kinase, trastuzumab targets HER2, and erlotinib inhibits EGFR.

**Pharmacokinetics**

- **Absorption:** Oral administration.
- **Distribution:** Varies by drug; trastuzumab is administered intravenously.
- **Metabolism:** Primarily hepatic (cytochrome P450 enzymes for small molecules).
- **Excretion:** Biliary and renal excretion.

**Adverse Effects**

- Diarrhea

- Rash (EGFR inhibitors)
- Cardiomyopathy (trastuzumab)
- Edema (imatinib)

**Uses**

- Chronic myeloid leukemia (CML)
- Breast cancer (HER2-positive)
- Non-small cell lung cancer (NSCLC)

**8. Immunotherapy**

**Examples:** Pembrolizumab, Nivolumab, Ipilimumab

**Mechanism of Action**

Immunotherapy drugs enhance the immune response against cancer cells by blocking immune checkpoints (PD-1, CTLA-4) or modulating immune activity.

**Pharmacokinetics**

- **Absorption:** Intravenous administration.
- **Distribution:** Extensive distribution in the body.
- **Metabolism:** Degraded by proteolytic enzymes.
- **Excretion:** Renal and hepatic pathways.

**Adverse Effects**

- Immune-related adverse events (irAEs) such as colitis, dermatitis, and hepatitis
- Fatigue
- Endocrinopathies

**Uses**

- Melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Hodgkin's lymphoma